NEW YORK--(BUSINESS WIRE)--The Global Alliance for TB Drug Development (TB Alliance) and the Novartis Institute for Tropical Diseases (NITD) announced today a five-year research collaboration designed to yield new medicines for TB, including drug-resistant TB. The partnership is a milestone toward the development of faster TB drug regimens that treat all forms of TB, are easier for patients to complete, and can be used safely in patients with HIV/AIDS.
